Cargando…
Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial
OBJECTIVES: To assess the costs of diagnostic workup and surgery of three strategies for patients with colorectal cancer liver-metastases (CRCLM): gadoxetic-acid-enhanced MRI (Gd-EOB-DTPA-MRI), MRI with extracellular contrast-media (ECCM-MRI) or contrast-enhanced MDCT (CE-MDCT). METHODS: The within-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052297/ https://www.ncbi.nlm.nih.gov/pubmed/26905871 http://dx.doi.org/10.1007/s00330-016-4271-0 |
_version_ | 1782458207520686080 |
---|---|
author | Zech, Christoph J. Justo, Nahila Lang, Andrea Ba-Ssalamah, Ahmed Kim, Myeong-Jin Rinde, Harald Jonas, Eduard |
author_facet | Zech, Christoph J. Justo, Nahila Lang, Andrea Ba-Ssalamah, Ahmed Kim, Myeong-Jin Rinde, Harald Jonas, Eduard |
author_sort | Zech, Christoph J. |
collection | PubMed |
description | OBJECTIVES: To assess the costs of diagnostic workup and surgery of three strategies for patients with colorectal cancer liver-metastases (CRCLM): gadoxetic-acid-enhanced MRI (Gd-EOB-DTPA-MRI), MRI with extracellular contrast-media (ECCM-MRI) or contrast-enhanced MDCT (CE-MDCT). METHODS: The within-trial cost evaluation was modelled as a decision-tree to calculate the cost of diagnosis and surgery. The model used clinical outcomes and resource utilization data from a prospective randomized multicentre study. Analyses were performed for the 354-patient safety population from eight participating countries. RESULTS: The diagnostic workup cost using Gd-EOB-DTPA-MRI upfront resulted in savings compared to ECCM-MRI in all countries except Thailand (difference <2 %). Compared to CE-MDCT, initial imaging with Gd-EOB-DTPA-MRI was less costly in all countries except Korea and Spain (differences 4 and 8 %, respectively). Significantly more patients in the Gd-EOB-DTPA-MRI group were eligible for surgery (39.3 % (48/122) vs. 31.0 % (36/116) and 26.7 % (31/116) for ECCM-MRI and CE-MDCT, respectively), allowing more patients to undergo potentially curative surgery, but resulting in higher treatment costs for the strategy starting with Gd-EOB-DTPA-MRI. CONCLUSIONS: The benefits of Gd-EOB-DTPA-MRI due to less additional imaging and similar diagnostic workup costs in the three groups suggest that Gd-EOB-DTPA-MRI should be the preferred initial imaging procedure to evaluate hepatic resectability in patients with CRCLM. KEY POINTS: • Diagnostic imaging cost to evaluate resectability was similar among the groups • Cost for imaging was rather small compared to the cost of surgery • Significantly more patients in the Gd-EOB-DTPA-MRI arm were eligible for surgery • Gd-EOB-DTPA-MRI is recommended for evaluating hepatic resectability in patients with CRCLM ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00330-016-4271-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5052297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-50522972016-10-20 Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial Zech, Christoph J. Justo, Nahila Lang, Andrea Ba-Ssalamah, Ahmed Kim, Myeong-Jin Rinde, Harald Jonas, Eduard Eur Radiol Hepatobiliary-Pancreas OBJECTIVES: To assess the costs of diagnostic workup and surgery of three strategies for patients with colorectal cancer liver-metastases (CRCLM): gadoxetic-acid-enhanced MRI (Gd-EOB-DTPA-MRI), MRI with extracellular contrast-media (ECCM-MRI) or contrast-enhanced MDCT (CE-MDCT). METHODS: The within-trial cost evaluation was modelled as a decision-tree to calculate the cost of diagnosis and surgery. The model used clinical outcomes and resource utilization data from a prospective randomized multicentre study. Analyses were performed for the 354-patient safety population from eight participating countries. RESULTS: The diagnostic workup cost using Gd-EOB-DTPA-MRI upfront resulted in savings compared to ECCM-MRI in all countries except Thailand (difference <2 %). Compared to CE-MDCT, initial imaging with Gd-EOB-DTPA-MRI was less costly in all countries except Korea and Spain (differences 4 and 8 %, respectively). Significantly more patients in the Gd-EOB-DTPA-MRI group were eligible for surgery (39.3 % (48/122) vs. 31.0 % (36/116) and 26.7 % (31/116) for ECCM-MRI and CE-MDCT, respectively), allowing more patients to undergo potentially curative surgery, but resulting in higher treatment costs for the strategy starting with Gd-EOB-DTPA-MRI. CONCLUSIONS: The benefits of Gd-EOB-DTPA-MRI due to less additional imaging and similar diagnostic workup costs in the three groups suggest that Gd-EOB-DTPA-MRI should be the preferred initial imaging procedure to evaluate hepatic resectability in patients with CRCLM. KEY POINTS: • Diagnostic imaging cost to evaluate resectability was similar among the groups • Cost for imaging was rather small compared to the cost of surgery • Significantly more patients in the Gd-EOB-DTPA-MRI arm were eligible for surgery • Gd-EOB-DTPA-MRI is recommended for evaluating hepatic resectability in patients with CRCLM ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00330-016-4271-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-02-24 2016 /pmc/articles/PMC5052297/ /pubmed/26905871 http://dx.doi.org/10.1007/s00330-016-4271-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Hepatobiliary-Pancreas Zech, Christoph J. Justo, Nahila Lang, Andrea Ba-Ssalamah, Ahmed Kim, Myeong-Jin Rinde, Harald Jonas, Eduard Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title | Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title_full | Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title_fullStr | Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title_full_unstemmed | Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title_short | Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial |
title_sort | cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: results from the value trial |
topic | Hepatobiliary-Pancreas |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052297/ https://www.ncbi.nlm.nih.gov/pubmed/26905871 http://dx.doi.org/10.1007/s00330-016-4271-0 |
work_keys_str_mv | AT zechchristophj costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT justonahila costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT langandrea costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT bassalamahahmed costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT kimmyeongjin costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT rindeharald costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial AT jonaseduard costevaluationofgadoxeticacidenhancedmagneticresonanceimaginginthediagnosisofcolorectalcancermetastasisintheliverresultsfromthevaluetrial |